Table 1 Patients characteristics, (n = 46).

From: A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation

Characteristics

n = 46

Age (years), median

61 (34–72)

Male, n (%)

27 (58.7%)

Primary disease, n (%)

  AML

16 (34.8%)

  ALL

4 (8.7%)

  CML

2 (4.3%)

  MDS

13 (28.2%)

  MM

4 (8.7%)

  NHL

7 (15.2%)

Stem cell source, n (%)

  Bone marrow

26 (56.5%)

  PBSC

16 (34.8%)

  Autologous/allogeneic

6 (13%)/10 (21.7%)

  Cord blood

4 (8.7%)

Conditioning therapy, n (%)

  MAC/RIC

23 (50%)/23 (50%)

  HLA match, n (%)

25 (54.3%)

Immunosuppressant, n (%)

  Corticosteroid

30 (65.2%)

  Cyclosporine

11 (23.9%)

  Tacrolimus

31 (67.4%)

  Mycophenolate mofetil

6 (13%)

  Short methotrexate

34 (73.9%)

 Anti-HBs at baseline, median

100.9 (<2.5–1000<)

 Anti-HBc at baseline, median

17.1 (1.2–124)

GVHD, n (%)

  Acute GVHD

29 (63%)

  Chronic GVHD

22 (47.8%)

Back to article page